Pilot Study of Meclofenamate in Subjects with Recurrent or Progressive Brain Metastasis from Solid Tumor Primary
Meclofenamate is a drug used to treat arthritis and other types of mild to moderate pain. Laboratory studies have shown that it can also inhibit the growth of cancers that have spread to the brain from other parts of the body (brain metastases).
In this study, researchers want to assess the effects of meclofenamate in patients with brain metastases that continue to grow despite prior treatment. Meclofenamate is taken orally (by mouth) twice a day.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients in this study must have brain metastases that persist despite prior therapy.
- Patients in this study must be able to have an MRI of the brain.
- This study is for patients age 18 to 80.
For more information about this study and to inquire about eligibility, please contact Dr. Adrienne Boire at 212-639-5371.